Tech companies Mitsui and NVIDIA have joined forces to develop what they say is the world’s first generative artificial intelligence supercomputer designed for use in phar
Shares in Esperion Therapeutics lost more than half of their value after it disclosed a dispute with Daiichi Sankyo on a $300 million milestone payment relating to cholest
Daiichi Sankyo has succeeded in a bid to convince the US Patent and Trademark Office (PTO) to take another look at a patent held by Seagen that was previously deemed to ha
The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be
Four Japanese drugmakers – Astellas, Eisai, Daiichi Sankyo, and Takeda – have joined forces in a partnership intended to reduce the environmental impact of pharmaceutical packaging.
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu is already making waves in breast cancer, and clinical results presented at the San Antonio Breast Cancer Symposium (S
Lonza has boosted its ability to cater for customers in the fast-emerging antibody-drug conjugate category with a deal to buy Dutch company Synaffix and its platform techn